Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 146 Melanoma 122 Breast Neoplasms 98 Squamous Cell Carcinoma of Head and Neck 94 Triple Negative Breast Neoplasms 84 Lung Neoplasms 63 Neoplasm Metastasis 53 Carcinoma, Renal Cell 49 Neoplasms 45 Head and Neck Neoplasms 44 Colorectal Neoplasms 40 Ovarian Neoplasms 38 Carcinoma, Transitional Cell 36 Carcinoma, Hepatocellular 36 Pancreatic Neoplasms 35 Urinary Bladder Neoplasms 34 Stomach Neoplasms 32 Recurrence 32 Glioblastoma 28 Brain Neoplasms 27 Sarcoma 26 Endometrial Neoplasms 24 Prostatic Neoplasms 23 Hodgkin Disease 22 Uterine Cervical Neoplasms 19 Fallopian Tube Neoplasms 19 Carcinoma, Squamous Cell 18 Esophageal Squamous Cell Carcinoma 17 Adenocarcinoma 17 Multiple Myeloma 16

Interventions

Fulvestrant 5 olaparib 4 Letrozole 4 Aromatase Inhibitors 3 Anastrozole 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Goserelin 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Capecitabine 2 talazoparib 1 sonidegib 1 ribociclib 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 elacestrant 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1 Vinorelbine 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡